GATA-4, a potential novel therapeutic target for high-grade meningioma, regulates miR-497, a potential novel circulating biomarker for high-grade meningioma
Caterina Negroni(University of Plymouth), C. Oliver Hanemann(University of Plymouth)
Cited by 41
Related Papers
Nilotinib alone or in combination with selumetinib is a drug candidate for neurofibromatosis type 2
|Neuro-Oncology|2011|54
Global Proteome and Phospho-proteome Analysis of Merlin-deficient Meningioma and Schwannoma Identifies PDLIM2 as a Novel Therapeutic Target
|EBioMedicine|2017|30
A novel patient-derived meningioma spheroid model as a tool to study and treat epithelial-to-mesenchymal transition (EMT) in meningiomas
|Acta Neuropathologica Communications|2023|15